[MO33] Mini-Oral Session 33　COVID-19 2

[MO33-2] Safety and Immunogenicity of BNT162b2 for Patients Undergoing Chemotherapy for Solid Cancers in Japan

^○Yohei Funakoshi¹, Kimikazu Yakushijin¹, Goh Ohji², Wataru Hojo³, Hironori Sakai³, Ryo Takai⁴, Taku Nose¹, Shinya Ohata¹, Yoshiaki Nagatani¹, Taiji Koyama¹, Akihito Kitao¹, Meiko Nishimura¹, Yoshinori Imamura¹, Naomi Kiyota^1,5, Kenichi Harada⁶, Yugo Tanaka⁷, Yasuko Mori⁸, Hironobu Minami^1,5 (1.Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine, 2.Division of Infection Disease Therapeutics, Department of Microbiology and Infectious Diseases, Kobe University Hospital and Graduate School of Medicine, 3.R&D, Cellspect Co., Ltd., 4.Division of Gastrointestinal Surgery, Department of Surgery, Kobe University Hospital and Graduate School of Medicine, 5.Cancer Center, Kobe University Hospital, 6.Division of Urology, Department of Surgery, Kobe University Hospital and Graduate School of Medicine, 7.Division of Thoracic Surgery, Department of Surgery, Kobe University Hospital and Graduate School of Medicine, 8.Division of Clinical Virology, Center for Infectious Diseases, Kobe University Graduate School of Medicine)